TNFRSF17 and Miyoshi myopathy: BITE therapies targeting BCMA/CD3, such as AMG 701, combined with immunomodulatory drugs (IMiDs) like lenalidomide and pomalidomide, have demonstrated enhanced anti-MM cytotoxicity and immunomodulatory effects in preclinical models [35].